A report has identified seven drugs launching this year that will reach blockbuster status by 2023.
The analysis is provided by Cortellis, part of the data company Clarivate Analytics, and looks at trends in the new drug launches forecast for the year ahead. Drugs forecasted to launch in 2019 are dominated by those treating immune-related and genetic disorders including spinal muscular atrophy (SMA), rheumatoid arthritis (RA) and peanut allergy.
The report says that this indicates a shift toward blockbuster-potential drugs targeting niche patient populations, buoyed by strong collaborations between big and specialty pharma companies to develop these therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze